drugset / Trial / NCT01175902

Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma

NCT01175902

RandomizedCrossoverOpen-labelTreatment

Summary

To prove the non-inferiority of the fixed timolol-dorzolamide combination (Cosopt) compared to 0.005% latanoprost (Xalatan) in the aspects of intraocular pressure (IOP) and ocular perfusion pressure (OPP) in subjects with normal tension glaucoma (NTG) Clinical hypotheses. Primary hypothesis * Cosopt group is non-inferior to Xalatan group in diurnal IOP reduction. Secondary hypothesis * Cosopt group is non-inferior to Xalatan group in diurnal diastolic and systolic OPP.

Timeline

Start
2011-03
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule Other
Comparator dorzolamide/timolol Unknown Other

Indications